New Hope for Patients with Wet Macular Degeneration
Three new drugs have been used to measurably improve the sight
of those suffering with the "wet" variety of macular degeneration.
Although macular degeneration is the most common cause of
blindness in those older than 50, only 10% of cases are of the wet variety.
Macugen, Lucentis, and Avastin represent new hope for patients with this
type, a condition caused when new vessels form in an effort to improve the
blood supply to oxygen-deprived retinal tissue. However, the new vessels
are very delicate and break easily, causing bleeding and damage to surrounding
tissue. Macugen and Lucentis, which are injected directly into the eye,
work by blocking VEGF, the natural substance that encourages the new growth.
Avastin, originally used as treatment for colon cancer, allows
the retina to drain fluid and return to its intended shape. Beneficial results
obtained with Avastin appear to last longer than those obtained by using
Lucentis or Macugen.
"I went from being quite dependent on my husband to being
able to drive legally," said Charlotte Warner, age 83, who participated
in a Macugen drug trial.
As with any drug breakthrough, cost is always a concern. Dawn
Kalmar, a representative of Genentech who produces Lucentis, says a price
has not yet been determined nor is it known if Medicare or other insurers
will provide coverage.
The current price for Macugen which is injected every six
weeks, is $995 per dose and is covered by some insurers and by Medicare.
Source: AARP Bulletin, 10-05
|
